SanBio Co., Ltd. (4592)
JPX JPX Primary 
OTC PINK Summary
SanBio Co., Ltd. (4592) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has SanBio Co., Ltd. ever had a stock split?
SanBio Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Keita Mori CEO | JPX Exchange | JP3336750009 ISIN |
| JP Country | 29 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
SanBio Company Limited is at the forefront of developing and commercializing innovative therapies for patients with central nervous system (CNS) conditions. Founded in 2001 and based in Tokyo, Japan, the company focuses on creating regenerative cell medicines that hold the potential to dramatically improve outcomes for individuals suffering from CNS diseases. SanBio's groundbreaking work revolves around its robust research pipeline and its flagship product, SB623, which has successfully completed phase 2 clinical trials in the United States and Japan for the treatment of traumatic brain injury. The company's dedication to addressing unmet medical needs spans across various CNS disorders, aiming to offer new hope through their cutting-edge cell therapy technologies.
Products and Services
- SB623: This regenerative cell medicine is designed for the treatment of traumatic brain injury and has reached a significant milestone by completing a phase 2 clinical trial in the United States and Japan. Beyond traumatic brain injury, SB623 is also being developed for other conditions, including:
- Ischemic strokes
- Hemorrhagic strokes
- Age-related macular degeneration
- Retinitis pigmentosa
- Parkinson's disease
- Spinal cord injury
- Alzheimer's disease
- SB618: A cell therapy product in development for the treatment of peripheral nerve damage, showcasing SanBio's commitment to addressing a wide range of neurological disorders.
- SB308: Focused on treating muscular dystrophy disease, this product highlights SanBio's dedication to tackling debilitating muscular and skeletal conditions through innovative cellular therapies.
- MSC1: In the oncology sphere, MSC1 is an investigatory product targeting the challenging field of cancer treatment, signifying SanBio's expansion into the development of therapies for malignancies.
- MSC2: This product is aimed at inflammatory diseases and optic neuritis, offering potential new treatments for conditions characterized by inflammation and immune system deregulation.
